Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18853889 | 0.82 | GPR84 (0.55) | GPR84HTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL20216311 | 0.82 | GPR84 (0.51) | GPR84HTR2AHTR2CHTR2BFFAR1 | |
| SCHEMBL15141744 | 0.80 | GPR84 (0.46) | GPR84HTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL15142092 | 0.79 | PKM (0.44) | GPR84NR3C1NR3C2TSHR | |
| SCHEMBL2309556 | 0.77 | GPR84 (0.49) | GPR84HTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL29003657 | 0.76 | GPR84 (0.45) | GPR84HTR2AHTR2CHTR2BNR3C1 | |
| Iodide SCHEMBL1295531 | 0.75 | GPR84 (0.47) | GPR84HTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL20458837 | 0.75 | GPR84 (0.44) | GPR84HTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL12671700 | 0.74 | HTR2A (0.72) | GPR84HTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL12671597 | 0.74 | HTR2A (0.72) | GPR84HTR2AHTR2CHTR2BNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | GPR84 2464/4885HTR2A 4866/4885HTR2C 4731/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | GPR84 2464/4885HTR2A 4866/4885HTR2C 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.